Premium
D‐dopachrome tautomerase is over‐expressed in pancreatic ductal adenocarcinoma and acts cooperatively with macrophage migration inhibitory factor to promote cancer growth
Author(s) -
Guo Dawei,
Guo Jinshuai,
Yao Junchao,
Jiang Kun,
Hu Jianhua,
Wang Bo,
Liu Haiyang,
Lin Lin,
Sun Wenyu,
Jiang Xiaofeng
Publication year - 2016
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.30278
Subject(s) - macrophage migration inhibitory factor , pancreatic cancer , cell growth , cancer research , gene knockdown , biology , protein kinase b , cell culture , signal transduction , cancer , microbiology and biotechnology , biochemistry , cytokine , immunology , genetics
Previous studies have established the important role of MIF in the development of pancreatic ductal adenocarcinoma (PDAC) for both therapeutic and diagnostic perspectives, but little is known about the expression and function of D‐dopachrome tautomerase (DDT), a functional homolog of MIF, in PDAC. In the present study, we demonstrated that DDT was over‐expressed in PDAC tissues in a pattern correlated with MIF. In the pancreatic cancer cell lines, PANC‐1, BXPC‐3 and ASPC‐1, both DDT and MIF were expressed and co‐localized with each other in the endosomal compartments and plasma membrane. Knockdown of DDT and MIF in PANC‐1 cells cooperatively inhibited ERK1/2 and AKT phosphorylation, increased p53 expression, and reduced cell proliferation, invasion and tumor formation. These effects were rescued by the re‐expression of MIF or DDT, but not by the forced expression of the tautomerase‐deficient mutants of DDT and MIF, P1G‐DDT and P1G‐MIF. Finally, we observed that 4‐iodo‐6‐phenylpyrimidine (4‐IPP), a covalent tautomerase inhibitor of both DDT and MIF, attenuated PANC‐1 cell proliferation and colony formation in vitro and tumor growth in vivo . Thus, targeting the tautomerase sites of both MIF and DDT may offer more efficient therapeutic benefits to PDAC patients.